Thrombin Generation Measured Ex Vivo Following Microvasculor Injury Is Increased in SLE Patients with Antiphospholipid-protein Antibodies

Summary

Antiphospholipid-protein antibodies (APA) include lupus-type anticoagulant (LA) and antibodies recognizing complexes of anionic phospholipids (e.g. cardiolipin) and proteins (e.g. prothrombin and (β₂-glycoprotein I). The presence of APA is associated with an increased risk of both arterial and venous thrombosis. However, the pathogenic mechanism leading to thrombosis in patients with APA remains unclear. We studied 32 patients with systemic lupus erythematosus (SLE) who were divided into two groups depending on the presence (n = 19) or absence (n = 13) of APA. Healthy volunteers (n = 12) matched by age and sex served as controls. In all subjects LA and IgG class anticardiolipin antibodies (ACA) were determined. Thrombin generation was monitored ex vivo measuring fibrinopeptide A (FPA) and prothrombin fragment F1 + 2 (F1 + 2) in blood emerging from a skin microvasculature injury, collected at 30 second intervals. In subjects with antiphospholipid antibodies mean FPA and F1 + 2 concentrations were signiF1cantly higher at most blood sampling times than in controls. In some SLE patients with APA the process of thrombin generation was clearly disturbed and very high concentrations of F1brinopeptide A were detected already in the F1rst samples collected. Two minutes after skin incision SLE patients without APA produced slightly more FPA, but not F1 + 2, as compared to healthy subjects. Mathematical model applied to analyze the thrombin generation kinetics revealed that APA patients generated signiF1cantly greater amounts of thrombin than healthy controls (p = 0.02 for either marker). In contrast, in the same patients generation of thrombin in recalciF1ed plasma in vitro was delayed pointing to the role of endothelium in the phenomenon studied. In summary, these data show for the F1rst time that in SLE patients with antiphospholipid-protein antibodies thrombin generation after small blood vessel injury is markedly increased. Enhanced thrombin generation might explain thrombotic tendency observed in these patients.

• References

• 1 Ghirardello A, Doria A, Ruffati A, Rigoli AM, Vesco P, Calligaro A, Gambari PF. antibodies in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?. Ann Rheum Dis 1994; 53: 140-142
• 2 Abu-Shakra M, Gladman DD, Urowitz MB. antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624-628
• 3 Conley CL, Hartmann RC. hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Lab Clin Invest 1952; 31: 621-622
• 4 Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
• 5 Harris EN, Gharavi AE, Boey ML, Patel BM, Loizou S, Hughes GR. antibodies: detection by radioimmunoassay and association with thrombosis in lupus erythematosus. Lancet 1983; 2: 1211-1214
• 6 Derksen RHWM, Hasselaar P, Blokzijl L, Meyling FHJG, de GrootPG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364-371
• 7 Ames PRJ, Pyke S, Iannaccone L, Brancaccio V. Antiphospholipid antibodies, haemostatic variables, and thrombosis - a survey of 144 patients. Thromb Haemost 1995; 73: 768-773
• 8 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” antibodies. Blood 1994; 84: 2854-2867
• 9 Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995; 78: 01-31
• 10 Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA. thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: Evidence for a prothrombotic state. Blood 1993; 81: 2958-2963
• 11 Ferro D, Quintarelli C, Valesisni G, Violi F. Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. Blood 1994; 83: 304
• 12 Gschwandtner ME, Eichinger S, Hütter D, Kominger L, Lechner K, Panzer S, Pabinger I. Lupus anticoagulant and thromboembolism: evaluation of fibrinogen, natural inhibitors and molecular markers of thrombosis. Blood Coagulat Fibrinol 1996; 7: 325-330
• 13 Debize G, Massignon D, Coeur P. Antiphospholipid antibodies and thrombotic risk: relationship to thrombomodulin, d-dimers and prothrombin fragments 1 + 2. Nouv Rev Fr Hematol 1995; 37 (Suppl. 02) 593-596
• 14 Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-2011
• 15 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CL, Harris EN. of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA). Clin Exp Immunol 1985; 62: 738-745
• 16 Brandt JT, Triplett DA, Alving B, Scharer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-1190
• 17 Pitney WR, Dacie JV. simple method of studying the generation of thrombin in recalcified plasma. J Clin Pathol 1953; 6: 09-13
• 18 Szczeklik A. Generation of the proteolytic activity bound with alpha 2- macroglobulin during plasma clotting. Clin Chim Acta 1970; 27: 339-344
• 19 Szczeklik A, Musial J, Undas A, Swadzba J, Gora PF, Piwowarska W, Duplaga M. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vase Biol 1996; 16: 948-954
• 20 Szczeklik A, Musial J, Dropiński J, Krzanowski M, Królikowski W, Undas A, Swadźba J, Duplaga M, Bodzoń W. Thrombinogenesis and its farmaco-logical modulation in atherosclerosis. J Physiol Pharmacol 1994; 45: 03-11
• 21 Harris EN. Syndrom of the black swan. Br J Rheumatol 1987; 26: 324-326
• 22 Hughes GRV. The antiphospholipid syndrome. Lupus 1996; 5: 345-346
• 23 Lie JT. Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is a culprit and vasculitis the consort. Lupus 1996; 5: 368-371
• 24 Hasselaar P, Derksen RH, Blokzijl L, de GrootP. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost 1990; 63: 169-173
• 25 Del PapaN. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity of resting and cytokine activated endothelial cells. Clin Exp Rheumatol 1992; 10: 37-42
• 26 Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus 1996; 5: 440-441
• 27 Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119: 819-827
• 28 Oosting JD, Derksen RHWM, Blokzij L, Sixma JJ, de GrootPG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis model. Thromb Haemost 1992; 68: 278-284
• 29 Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulant and antibodies to phospholipid. JAMA 1988; 259: 550-4
• 30 Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994; 3: 247-251
• 31 de GrootPG, Horbach DA, Derksen RHWM. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996; 5: 488-493
• 32 Ames PRJ, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-194